Reimagine Cancer Detection, Diagnosis & Patient Management through Harnessing the Potential of Liquid Biopsies

In the past year, the detection and characterization of fluid-based biomarkers in oncology witnessed an unprecedented level of progress, investment and industry partnership announcements. However, as the liquid assay landscape matures and the level of sensitivity and selectivity achieved by assays creates excitement for precision drug development, there remains a number of unique hurdles to translate rapid technical advancements seen towards the development of more effective and accessible precision oncology treatments.

That’s why the 6th Liquid Biopsy for Precision Oncology Summit will take place this February in San Diego, giving you the first opportunity in over a year to network, collaborate with and learn directly from your peers at a face-to-face forum.

As industry’s most comprehensive liquid biopsy meeting, unite with 300+ key decision makers including Pfizer, AstraZeneca, Mirati Therapeutics, Kura Oncology, GSK, BloodPAC, International Society of Liquid Biopsy, Guardant Health, Natera and many more to address the key scientific, technical, regulatory, commercial and testing access challenges associated with progressing precision oncology pipelines harnessing liquid biopsy technology.

With the rise of early detection and IO assays, expansion of MRD monitoring, CDx reimbursement announcements and a wealth of therapeutically relevant biomarkers being identified, here lies your prime opportunity to meet diverse stakeholders, in person, and discover the most cutting-edge scientific data to strengthen your pipeline and capitalize on the vast amount of progress the field is witnessing.

Andrew Allen

President, Chief Executive Officer & Co-Founder

Gritstone bio

George Vasmatzis

Co Director - Biomarker Discovery Program

Mayo Clinic

Julie Ramage

Director of Precision Medicine Quality Initiatives & Partnerhips


Kelly Shanahan


Living with Metastatic Breast Cancer

Kenna Anderes

Vice President Translational Medicine & Companion Diagnostics

Mirati Therapeutics

Koustubh Ranade

Head of Translational Medicine


Lauren Leiman

Executive Director


Marjorie Petty

Senior Director, Operations & Medical Development

Spectrum Pharmaceuticals

Partha Das

Medical Director, CDx & Biomarker Strategy


Qu Zhang

Director, Clinical Biomarkers, ImmunoOncology


How Are We Advancing Your Delivery of Precision Therapeutics in 2022?

Bringing together leading experts, practitioners and technical decision makers, this is your opportunity to hear how fluid based biodetection is improving for circulating biomarkers with potential to fast-track your pipeline candidates towards the clinic.

Joined by the likes of the MD Anderson Cancer Center, City of Hope, Pfizer, Mirati Therapeutics, Janssen & many more, you can gain insights from those leading the way when it comes to harnessing the latest liquid biopsy techniques and technologies in drug development program design.

With collaborations integral to furthering the promise of precision medicine, this community meeting is supporting a whole host of ways you can maintain those touchpoints with like-minded leaders. Meet in-person to share, seek inspirations and best practice from your fellow colleagues to address common pipeline challenges.

Why Should You Attend?

If you have interest in the application of fluid-based biomarkers detection and characterization to improve the speed of delivery, safety and precision of therapies reaching patients in need, this meeting is designed with you in mind.

For tangible insights you can use to create robust commercial and clinical strategies, accelerate drug development timelines, and maximize patient access to your pipeline portfolio, look no further than the 6th Liquid Biopsy for Precision Oncology Summit!

What’s more, passes are free to attend for drug developers & researchers!

Don’t take our word for it! Here’s what past attendees had to say at last year’s digital meeting!

“I learned the latest progress in use of liquid biopsy in both the research and clinical setting. Wouldn't miss this meeting” –  Genentech


““Extremely informative sessions which provide insight into both the clinical and commercial potential of liquid biopsy” – Myriad Genetics


“Liquid Biopsy has finally come of age as evident by the speakers and presentations given at the Liquid Biopsy Summit” – Regeneron

Lead Partner


Expertise Partner


Program Partners

Burning Rock cropped (002)
epic sciences logo
NuProbe Logo (002)
Biodesix (002)
Personalis (002)

Spotlight Partners

PGDx logo (002)

Other Events in the Series